{
  "id": 1645970,
  "title": "Changing fortunes: is Biotech giant CSL’s $10 billion write-down a comeback story?",
  "url": "https://urgent.news/2026/08/18/changing-fortunes-is-biotech-giant-csls-10-billion-write-down-a",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T05:51:19.000Z",
  "source": {
    "name": "The Sydney Morning Herald",
    "slug": "the-sydney-morning-herald",
    "url": "https://www.smh.com.au/business/companies/changing-fortunes-is-biotech-giant-csl-s-10-billion-write-down-a-comeback-story-20260818-p60pcd.html?ref=rss"
  },
  "original_language": "en",
  "account": null,
  "summary": "Make no mistake: the home-grown biotechnology company, which for decades allowed Australia serious boasting rights, is still a long way from redemption.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Age",
        "title": "Changing fortunes: is Biotech giant CSL’s $10 billion write-down a comeback story?",
        "url": "https://urgent.news/2026/08/18/changing-fortunes-is-biotech-giant-csls-10-billion-write-down-a-1646410",
        "published": "2026-08-18T05:51:19.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}